Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2056 to 2070 of 8852 results

  1. Obinutuzumab for treating primary membranous nephropathy [ID6751]

    Awaiting development Reference number: GID-TA11983 Expected publication date: TBC

  2. Itopride hydrochloride for treating gastrointestinal symptoms of functional dyspepsia [ID6745]

    Awaiting development Reference number: GID-TA11979 Expected publication date: TBC

  3. Tislelizumab for treating unresectable advanced oesophageal squamous cell cancer after platinum-based chemotherapy (review of TA1068) [ID6682]

    Awaiting development Reference number: GID-TA11978 Expected publication date: TBC

  4. Elacestrant with everolimus for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment [ID6753]

    Awaiting development Reference number: GID-TA11973 Expected publication date: TBC

  5. Bictegravir–lenacapavir for treating HIV-1 [ID6744]

    Awaiting development Reference number: GID-TA11970 Expected publication date: TBC

  6. Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable [ID6736]

    Awaiting development Reference number: GID-TA11964 Expected publication date: TBC

  7. Encorafenib with cetuximab and FOLFOX for untreated BRAF V600E mutation-positive metastatic colorectal cancer [ID6734]

    Awaiting development Reference number: GID-TA11961 Expected publication date: TBC

  8. Technologies for the detection of Hepatocellular Carcinoma

    Awaiting development Reference number: GID-HTG10175 Expected publication date: TBC

  9. Emtricitabine/tenofovir alafenamide for human immunodeficiency virus type-1 infection [TSID10723]

    Topic prioritisation

  10. Dupilumab for maintenance treatment of uncontrolled moderate to severe asthma in children 6 to 11 years [TSID10085]

    Topic prioritisation

  11. Glucarpidase for reducing toxic plasma methotrexate levels in people aged 28 days and over [TSID10761]

    Topic prioritisation

  12. Bardoxolone methyl for treating chronic kidney disease in people 12 years and over with Alport syndrome [TSID9998]

    Topic prioritisation

  13. Subcutaneous belimumab for treating systemic lupus erythematosus in children aged 5 to 17 [TSID11828]

    Topic prioritisation

  14. Avtozma (tocilizumab biosimilar) for treating moderate to severe rheumatoid arthritis in people aged 18 to 75 [TSID11848]

    Topic prioritisation

  15. Dapsone for treating COVID-19 in people 40 years and over with high-risk comorbidity and people 70 years and over [TSID11892]

    Topic prioritisation